Hangzhou Biotest Stock Hits Day Low of CNY 37.82 Amid Price Pressure

Hangzhou Biotest Biotech Co., Ltd. experienced a significant decline today, with the stock dropping by 7.67%. The stock reached an intraday low of CNY 37.82, reflecting a challenging market environment for the mid-cap pharmaceuticals and biotechnology company. Over the past week, Hangzhou Biotest has seen a decrease of 4.7%, while its performance over the past month shows a modest increase of 6.24%. However, the longer-term outlook remains concerning, with a year-to-date performance of just 1.01% and a notable decline of 14.13% over the past year, contrasting sharply with the China Shanghai Composite's gain of 20.96% during the same period. Financial metrics indicate ongoing difficulties, including a significant drop in net sales by 13.84% and a net profit of CNY 9.86 million, which has fallen by 42.12%. The company's debt-equity ratio stands at -0.59, highlighting financial strain. With a P/E ratio of 54.00, the stock's valuation reflects investor sentiment amid these challenges.